All News

As more novel therapies emerge from the pipeline and enter the market, it is crucial for pharmacists to monitor new drug approvals that could be lifechanging for their patients.

Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.

Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.

Patients must be counseled about the risk of acute or chronic liver steatosis associated with all prescription and over the counter medications.

Top news of the day from across the health care landscape.

You know what DNA is, but do you really know what leadership is?

A ‘fail-first’ policy by the Centers for Medicare and Medicaid Services could be a nightmare for patients with cancer, according to the Community Oncology Alliance.

The importance of improving the specialty pharmacy experience for patients newly diagnosed with a life-changing disease.

The oral tablets under review by the FDA should be paired with rest, physical therapy and other measures, according to manufacturer Galt Pharmaceuticals.

Many patients with pancreatic cancer do not receive cancer-directed treatment that may extend survival.

Top news of the day from across the health care landscape.

The approval of R2 is based on data from the phase 3 AUGMENT study evaluating the safety and efficacy of the combination regimen compared with rituximab plus placebo in patients with previously-treated FL and MZL.

Effective treatment with ART has increased the life span of people living with HIV, but they remain at risk for chronic diseases.

Officials with the FDA today approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product (R2) for the treatment of adult patients with previously-treated follicular lymphoma or marginal zone lymphoma.

The new indication makes cariprazine the first and only dopamine and serotonin partial agonist to treat the full spectrum of bipolar I symptoms in manic, mixed, and depressive episodes.

The new indication makes cariprazine (Vraylar, Allergan and Gedeon Richter) the first and only dopamine and serotonin partial agonist to treat the full spectrum of bipolar I symptoms in manic, mixed, and depressive episodes, according to the companies.

The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.

Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.

Genomic data may improve the selection of more precise models for metastatic breast cancer research.

Top news of the day from across the health care landscape.

What is causing the visual distrubances in this young man?

Officials with the FDA approved ruxolitinib (Jakafi, Incyte), the first treatment for patients 12 years and older with steroid-refractory acute graft-versus-host disease.

Ruxolitinib is the first and only FDA-approved treatment for this indication, according to Incyte, the drug's manufacturer.

Officials with the FDA have approved alpelisib (Piqray, Novartis) tablets, to be used in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.

The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.

The study included an analysis detailing crash and traffic violation records for newly licensed drivers. It is the first large-scale longitudinal study on this topic.

Top news of the week from Specialty Pharmacy Times.